Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Englishtown, New Jersey 07726


Purpose:

RATIONALE: Monoclonal antibodies, such as Cetuximab, can target tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.This is an anti-cancer drug which has already been approved by the FDA for use in patients who have Colorectal Cancer. Cetuximab can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation Therapy uses high-energy x-rays to kill tumor cells and cause less damage to normal tissue . Giving the drug Cetuximab together with Radiation Therapy may kill more tumor cells. Surgery is the most common treatment for Colorectal Cancer to remove the tumor, as well as a small margin of surrounding normal tissue and possibly nearby lymph nodes. Surgery is usually used in conjunction with other conventional treatments such as Radiation Therapy. Radiation Therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Radiation Therapy after surgery may kill any tumor cells that remain after surgery. Screening test such as Fecal Occult Blood Test (FOBT) and Colonoscopy has to be done. Tumor markers for Colorectal Carcinoma are Carcinoembryonic antigen (CAE) and CA 19-9 and to assess the response of tumor markers Carcinoembryonic antigen (CAE) and CA 19-9 will be used and periodically Colonoscopy has to be done. Colorectal Cancer Surgery are Colon resection (Colectomy), Rectum resection (Proctectomy), Colostomy, and Radiofrequency ablation. PURPOSE: Determine the tumor response rate treated with Cetuximab and Radiation Therapy Vs Surgery before or after Radiation Therapy in patients with Colorectal Cancer from stage II to IV


Study summary:

OBJECTIVES: Primary: - Determine the response rate in patients with Colorectal Cancer treated with Cetuximab and Radiation Therapy Vs Surgery before or after Radiation Therapy. Secondary: - To determine the progression-free survival and overall survival of patients treated with these regimens. - Compare the treatment compliance of patients treated with these regimens. - Compare the safety of these regimens in these patients. OUTLINE: This is an Open-label, Controlled, Multicenter study. Patients will be assigned into two different Arms. Arm I: Patients will receive Cetuximab and Radiation Therapy. Patients will receive a dose of Cetuximab through Intravenous (IV). The initial dose is 400 mg/m2 administered as a 120-minute intravenous infusion (maximum infusion rate 10 mg/min) and weekly dose is 250 mg/m2 infused over 60 minutes (maximum infusion rate 10 mg/min) until disease progression or unacceptable toxicity. Radiation treatment for Colorectal Cancer are Intensity Modulated Radiation Therapy (IMRT). IMRT delivers radiation directly to the tumor and modulates the intensity of the radiation with laser accuracy. Arm II: Patients will undergo surgery before or after Radiation Therapy. Colorectal Cancer Surgery are Colon resection (Colectomy), Rectum resection (Proctectomy), Colostomy, and Radiofrequency ablation. Radiation treatment for Colorectal Cancer are Intensity Modulated Radiation Therapy (IMRT). IMRT delivers radiation directly to the tumor and modulates the intensity of the radiation with laser accuracy. PROJECTED ACCRUAL: Approximately 450 patients will be accrued for this study within 18 to 24 months.


Criteria:

Inclusion Criteria: - Patients with stage II- IV Colorectal Cancer - Patients must be 40 years and older - Patients may be of any race and either gender - Signed Informed Consent Patient characteristics: - Age: 40 years and older - Sex: Both - Performance status: Not specified - Life expectancy: Not specified Hematopoietic: - Granulocyte count ≥ 1,500/mm^3 - Platelet count ≥ 100,000/mm^3 - Hemoglobin ≥ 9.0 g/dL - No history of significant bleeding events within the past 6 months Hepatic: - Bilirubin ≤ 1.5 mg/dL - Albumin ≥ 2.5 g/dL Renal: - Creatinine ≤ 1.5 times upper limit of normal - Protein < 1+ by urinalysis - Protein < 1 g by 24-hour urine collection Cardiovascular: - No conduction defect in heart - No congestive heart failure - No myocardial infarction within last 6 months - No cerebrovascular accident - No uncontrolled hypertension - No clinically significant peripheral artery disease Pulmonary: - No pulmonary embolism - No interstitial pneumonia - No extensive or symptomatic interstitial fibrosis of the lung Neurologic: - No uncontrolled seizure disorder - No active neurological disease Other: - Not pregnant or nursing - Negative pregnancy test Exclusion Criteria: - Age below 40 years - Brain or nervous system metastases - Any current mental illness - Hemoglobin is less than 9.0 g/dl - CBC results are below normal range - Patients with Hepatitis B or C or who are HIV positive - Pregnant or nursing patients are not eligible for entry into the study - Hepatic abnormality AST/ALT > 4 folds


NCT ID:

NCT00725400


Primary Contact:

Study Chair
Ratna Grewal, MD
American Scitech International- eCRO


Backup Contact:

N/A


Location Contact:

Englishtown, New Jersey 07726
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: January 18, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.